Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +44 1494 818025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Business Manager
claire@zenopa.com
+44 1494 818025

Testimonials
Within my time at Zenopa, I have found my Contractor Manager to offer the most fantastic support! The transition from my previous contract house was seamless and all the processes with Zenopa are very...
Jaz, 2012

GlaxoSmithKline enters partnership for nicotine vaccine

17 November 2009 00:00 in Pharmacy Supplier News


GlaxoSmithKline has been granted the licensing agreement for the nicotine conjugate candidate vaccine NicVAX from Nabi.

The vaccine is currently under trial for the treatment of nicotine addiction and the prevention of a smoking relapse.

Additionally, the agreement between the two firms extends to the development of a second similar product.

As part of the contract, Nabi will be paid an upfront sum of $40 million (23.7 million pounds) and will retain the option to in-license NicVAX worldwide.

Jean Stephenne, president of GSK Biologicals, stated: "If approved, this smoking cessation vaccine technology could be a novel solution to help the millions of smokers who want to stop smoking and remain abstinent."

Meanwhile, another GlaxoSmithKline product - its H1N1 influenza virus vaccine - was approved by the Food and Drug Administration last week.

Other news stories from 17/11/2009

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



             
© Copyright 2013 Zenopa Ltd